Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tenitramine is a small molecule organic nitrate that functions as a nitrovasodilator in cardiac therapy. It is primarily indicated as an antianginal agent for the treatment and prevention of angina pectoris. The drug acts as a nitric oxide donor; upon administration, it releases nitric oxide (NO), which activates soluble guanylate cyclase. This activation leads to increased levels of cyclic guanosine monophosphate (cGMP), resulting in the relaxation of vascular smooth muscle and subsequent vasodilation. This process reduces both cardiac preload and afterload, thereby decreasing myocardial oxygen demand and improving coronary blood flow. Tenitramine is categorized under the ATC code C01DA38 and has been historically marketed under the brand name Tinitran.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tenitramine.